Argenx Se (ARGX) Raw Materials (2020 - 2024)
Argenx Se's (ARGX) quarterly Raw Materials came in at $250.9 million in Q2 2024, up 121.78% YoY from $113.1 million in Q3 2023, and up 4.18% on a QoQ basis from $240.8 million in Q4 2023.
Argenx Se (ARGX) Raw Materials (2020 - 2024) Analysis & Trends
Argenx Se (ARGX) has 5 years of Raw Materials data on file, last reported at $250.9 million in Q2 2024.
- Quarterly Raw Materials rose 121.78% year-over-year to $250.9 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $250.9 million (up 121.78% YoY) and the FY2023 annual result came in at $240.8 million, up 91.07% from the prior year.
- Raw Materials improved to $250.9 million in Q2 2024, from $240.8 million in the prior quarter.
- In the past five years, Raw Materials ranged from a high of $250.9 million in Q2 2024 to a low of $5.5 million in Q2 2020.
- A 5-year average of $102.3 million and a median of $70.1 million in 2021 frame the typical range for Raw Materials.
- Annual changes were most pronounced in 2021 — Raw Materials jumped 652.1% — and 2022, when it jumped 33.32%.
- Tracing ARGX's Raw Materials over 5 years: stood at $18.1 million in 2020, then jumped by 287.91% to $70.1 million in 2021, then surged by 79.72% to $126.0 million in 2022, then jumped by 91.07% to $240.8 million in 2023, then rose by 4.18% to $250.9 million in 2024.
- The last three Raw Materials figures came in at $250.9 million (Q2 2024), $240.8 million (Q4 2023), and $113.1 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 250.89 Mn |
| Dec 31, 2023 | 240.84 Mn |
| Jun 30, 2023 | 113.13 Mn |
| Dec 31, 2022 | 126.05 Mn |
| Jun 30, 2022 | 54.97 Mn |
| Dec 31, 2021 | 70.13 Mn |
| Jun 30, 2021 | 41.23 Mn |
| Dec 31, 2020 | 18.08 Mn |
| Jun 30, 2020 | 5.48 Mn |